The optimal time for the initiation of in vitro fertilization and embryo transfer among women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertility-sparing treatment

[1] Chen W(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132

[2] Zheng R(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[3] Baade PD(2007)Prognostic factors for uterine cancer in reproductive-aged women Obstet Gynecol 109 655-662

[4] Zhang S(2015)European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility sparing management in young endometrial cancer patients Int J Gynecol Cancer 25 1258-1265

[5] Zeng H(2016)ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Ann Oncol 27 16-41

[6] Bray F(2015)Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer Int J Gynaecol Obstet 131 234-239

[7] Siegel RL(2015)Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients Gynecol Oncol 139 424-428

[8] Miller KD(2016)Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia Reprod Biol Endocrinol 14 2-66

[9] Jemal A(2011)Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: case series and literature review Taiwan J Obstet Gynecol 50 62-12

[10] Lee NK(2012)Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta analysis Am J Obstet Gynecol 207 266.e1-1269

[1] Chen W(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132

[2] Zheng R(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[3] Baade PD(2007)Prognostic factors for uterine cancer in reproductive-aged women Obstet Gynecol 109 655-662

[4] Zhang S(2015)European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility sparing management in young endometrial cancer patients Int J Gynecol Cancer 25 1258-1265

[5] Zeng H(2016)ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Ann Oncol 27 16-41

[6] Bray F(2015)Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer Int J Gynaecol Obstet 131 234-239

[7] Siegel RL(2015)Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients Gynecol Oncol 139 424-428

[8] Miller KD(2016)Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia Reprod Biol Endocrinol 14 2-66

[9] Jemal A(2011)Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: case series and literature review Taiwan J Obstet Gynecol 50 62-12

[10] Lee NK(2012)Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta analysis Am J Obstet Gynecol 207 266.e1-1269